FDA
-
-
-
-
-
-
-
Ascendis shows combination therapy benefits in achondroplasia trial
-
-
-
-
-
-
-
New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52
-
-
-
-
-
-
-
FDA approves YUVIWEL for children with achondroplasia
-
-
-
-
-
-
-
Ascendis reports positive 52-week trial data for achondroplasia treatment
-
-
-
-
-
-
-
Where can biotech stocks go from here? RBC answers
-
-
-
-
-
-
-
SKYTROFA receives FDA approval for adult growth hormone deficiency
-
-
-
-
-
-
-
NEW THERAPY FOR CHILDREN WITH GROWTH HORMONE DEFICIENCY APPROVED IN AUSTRALIA
-
325,120 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

